Accueil › Carcinome épidermoïde de la tête et du cou › Californie › Los Angeles
Essais cliniques pour Carcinome épidermoïde de la tête et du cou à Los Angeles, CA
42 études pour Carcinome épidermoïde de la tête et du cou recherchent des participants dans et autour de Los Angeles (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Recrutement en coursPhase 2
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- et 1 autres
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Recrutement en coursPhase 1
- Keck School of Medicine of USC, Los Angeles
- UCLA, Los Angeles
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Recrutement en coursPhase 2/3
- Site #0106, Los Angeles
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Recrutement en coursPhase 3
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Recrutement en coursPhase 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Recrutement en coursPhase 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Recrutement en coursPhase 1
- Research Site, Los Angeles
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Recrutement en coursPhase 2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Recrutement en coursPhase 3
- UCLA Hematology Oncology, Los Angeles
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Recrutement en coursPhase 3
- Valkyrie Clinical Trials, Los Angeles
- University of California, Los Angeles UCLA, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Recrutement en coursPhase 1/2
- University of Southern California, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
Recrutement en coursPhase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recrutement en coursPhase 2
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Recrutement en coursPhase 1
- Site 105 - START Los Angeles, Los Angeles
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Recrutement en coursÉtude observationnelle
- USC/Norris Comprehensive Cancer Center, Los Angeles
- University of California, Los Angeles, Los Angeles
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 1/2
- START Los Angeles, Los Angeles
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1
- University of Southern California, Los Angeles
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recrutement en coursPhase 2
- University of California Los Angeles, Los Angeles
- Samuel Oschin Cancer Center, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Recrutement en coursPhase 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recrutement en coursPhase 1/2
- Los Angeles Cancer Network, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Recrutement en coursPhase 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- Ellison Clinic at Saint John's, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Recrutement en coursPhase 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Recrutement en coursPhase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Recrutement en coursPhase 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Recrutement en coursPhase 1
- Start Lacn, Los Angeles
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Recrutement en coursPhase 3
- GSK Investigational Site, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Recrutement en coursPhase 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Recrutement en coursPhase 3
- University of California Los Angeles, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
Recrutement en coursPhase 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Recrutement en coursPhase 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Recrutement en coursPhase 1
- USC - Norris Comprehensive Cancer Center, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Recrutement en coursPhase 1/2
- University of Southern California, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Recrutement en coursPhase 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Recrutement en coursPhase 1/2
- University of Southern California, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Recrutement en coursPhase 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Recrutement en coursPhase 1
- University of Southern California, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Recrutement en coursPhase 1/2
- UCLA Medical Center, Los Angeles
Essais pour Carcinome épidermoïde de la tête et du cou dans d'autres villes
- Houston, TX47 études
- Boston, MA40 études
- Nashville, TN39 études
- New York City, NY39 études
- St. Louis, MO28 études
- Arlington, VA26 études
- Chicago, IL26 études
- Philadelphia, PA25 études
- Atlanta, GA24 études
- San Antonio, TX22 études
- Pittsburgh, PA22 études
- New Haven, CT22 études
Autres études à Los Angeles
- Cancer du poumon non à petites cellules87 études
- Cancer (tous types)74 études
- Cancer du sein72 études
- Cancer colorectal60 études
- Cancer de la prostate60 études
- Cancer métastatique57 études
- Cancer de l'ovaire50 études
- Cancer du poumon45 études
- Cancer du pancréas35 études
- Mélanome34 études
- Cancer de l'endomètre34 études
- Cancer du sein triple négatif26 études
Source : ClinicalTrials.gov, données récupérées le 7 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.